Q-omics provides the consensus-scored NDUFS8 profile across patient tissues and cancer cell-line models. NDUFS8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NDUFS8 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, NDUFS8 protein abundance shows 24,279 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, LIHC, and GBM as cancer lineages where NDUFS8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFS8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFS8 survival associations across molecular data types. NDUFS8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFS8 RNA expression–survival associations across cancer types. High NDUFS8 expression shows unfavorable associations in KIRC, UVM, HNSC, UCS and LIHC, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NDUFS8 RNA expression.
This table summarizes NDUFS8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFS8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFS8 shows lower tumor expression in KIRC and higher tumor expression in LIHC, LUAD, BLCA, LUSC and UCEC. The LIHC box plot shows higher NDUFS8 RNA expression in tumor versus normal tissue (log2 FC = +1.203, t-test p < 0.001).
This table shows molecular features associated with NDUFS8 in patient tissues and cancer cell lines. In patient samples, NDUFS8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFS8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
